Citius Pharmaceuticals (CTXR) News Today $2.73 +0.15 (+5.81%) (As of 12/17/2024 05:46 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Citius Pharma Held Productive FDA Meeting To Discuss Phase 3 Mino-Lok Program, Pathway To ApprovalNovember 25, 2024 | markets.businessinsider.comCitius Pharmaceuticals reports ‘constructive’ FDA Type C meeting on Mino-LokNovember 25, 2024 | markets.businessinsider.comCitius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to ApprovalNovember 25, 2024 | prnewswire.comD. Boral Capital Downgrades Citius Pharmaceuticals (CTXR)November 23, 2024 | msn.comCitius Pharmaceuticals downgraded to Hold from Buy at D. Boral CapitalNovember 23, 2024 | markets.businessinsider.comCitius Pharmaceuticals announces 1-for-25 reverse stock splitNovember 23, 2024 | markets.businessinsider.comCitius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock SplitNovember 22, 2024 | prnewswire.comCitius Pharmaceuticals Announces Closing of $3 Million Registered Direct OfferingNovember 18, 2024 | prnewswire.comCitius Pharmaceuticals Announces $3 Million Registered Direct OfferingNovember 15, 2024 | prnewswire.comEquities Analysts Issue Forecasts for CTXR FY2024 EarningsCitius Pharmaceuticals, Inc. (NASDAQ:CTXR - Free Report) - Equities research analysts at HC Wainwright decreased their FY2024 earnings per share estimates for shares of Citius Pharmaceuticals in a note issued to investors on Tuesday, November 12th. HC Wainwright analyst V. Bernardino now expectsNovember 14, 2024 | marketbeat.comWhat is HC Wainwright's Forecast for CTXR Q1 Earnings?Citius Pharmaceuticals, Inc. (NASDAQ:CTXR - Free Report) - Investment analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Citius Pharmaceuticals in a research note issued on Tuesday, November 12th. HC Wainwright analyst V. Bernardino anticipates that thNovember 13, 2024 | marketbeat.comBuy Rating for Citius Pharmaceuticals: Promising Clinical Results and Strong Financial OutlookNovember 13, 2024 | markets.businessinsider.comCitius Pharmaceuticals’ Lymphir and Keytruda Combo Shows Promising Clinical Outcomes, Earning a Buy RatingNovember 13, 2024 | markets.businessinsider.comHC Wainwright Reiterates Buy Rating for Citius Pharmaceuticals (NASDAQ:CTXR)HC Wainwright reaffirmed a "buy" rating and set a $4.00 price objective on shares of Citius Pharmaceuticals in a report on Tuesday.November 12, 2024 | marketbeat.comCitius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid TumorsNovember 11, 2024 | prnewswire.comCitius Pharma (NASDAQ:CTXR) Stock, Short Interest ReportOctober 7, 2024 | benzinga.comCitius Pharmaceuticals, Inc. (NASDAQ:CTXR) Sees Significant Decrease in Short InterestCitius Pharmaceuticals, Inc. (NASDAQ:CTXR - Get Free Report) saw a significant decrease in short interest in the month of September. As of September 15th, there was short interest totalling 12,530,000 shares, a decrease of 6.4% from the August 31st total of 13,390,000 shares. Based on an average trading volume of 2,170,000 shares, the days-to-cover ratio is presently 5.8 days.September 30, 2024 | marketbeat.comArmistice Capital LLC Acquires Shares of 10,156,000 Citius Pharmaceuticals, Inc. (NASDAQ:CTXR)Armistice Capital LLC acquired a new position in Citius Pharmaceuticals, Inc. (NASDAQ:CTXR - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 10,156,000 shares of the company's stSeptember 26, 2024 | marketbeat.comCitius Pharmaceuticals defers FDA milestone paymentSeptember 15, 2024 | uk.investing.comCitius Pharmaceuticals faces potential Nasdaq delistingSeptember 14, 2024 | uk.investing.comCitius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 5, 2024 | prnewswire.comCitius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in OncologySeptember 5, 2024 | prnewswire.comCitius Pharmaceuticals, Inc. (NASDAQ:CTXR) Sees Large Drop in Short InterestCitius Pharmaceuticals, Inc. (NASDAQ:CTXR - Get Free Report) was the recipient of a significant drop in short interest in the month of August. As of August 15th, there was short interest totalling 12,280,000 shares, a drop of 16.1% from the July 31st total of 14,630,000 shares. Based on an average daily volume of 2,250,000 shares, the days-to-cover ratio is presently 5.5 days.September 3, 2024 | marketbeat.comCTXR Oct 2024 2.000 callAugust 21, 2024 | ca.finance.yahoo.comBuy Rating Affirmed for Citius Pharmaceuticals Amid Strategic Oncology Spinout and Promising Lead Product DataAugust 17, 2024 | markets.businessinsider.comTenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination with Citius Oncology, and Provides Market UpdateAugust 13, 2024 | finanznachrichten.deCitius Pharmaceuticals (NASDAQ:CTXR) Releases Earnings Results, Misses Estimates By $0.01 EPSCitius Pharmaceuticals (NASDAQ:CTXR - Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.06) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.01).August 13, 2024 | marketbeat.comCitius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business UpdateAugust 12, 2024 | prnewswire.comCitius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc.August 12, 2024 | prnewswire.comCitius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming DevelopmentsAugust 12, 2024 | prnewswire.comCitius wins FDA nod for Lymphir in cutaneous T-cell lymphomaAugust 9, 2024 | msn.comUS FDA approves Citius' blood cancer therapyAugust 8, 2024 | reuters.comCitius Pharmaceuticals Receives FDA Approval for LYMPHIR™ (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell LymphomaAugust 8, 2024 | prnewswire.comStock Traders Purchase High Volume of Call Options on Citius Pharmaceuticals (NASDAQ:CTXR)Citius Pharmaceuticals, Inc. (NASDAQ:CTXR - Get Free Report) saw unusually large options trading activity on Tuesday. Stock traders acquired 6,590 call options on the company. This is an increase of 1,308% compared to the average daily volume of 468 call options.August 6, 2024 | marketbeat.comCitius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc.August 5, 2024 | prnewswire.comWhen Will Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Turn A Profit?July 22, 2024 | finance.yahoo.comEcon Corp Services DBA Investorideas.com: Biotech Stocks Race Towards Solutions for Cutaneous T-Cell Lymphoma (CTCL)July 20, 2024 | finanznachrichten.deShort Interest in Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Drops By 8.5%Citius Pharmaceuticals, Inc. (NASDAQ:CTXR - Get Free Report) saw a significant decline in short interest in June. As of June 30th, there was short interest totalling 14,150,000 shares, a decline of 8.5% from the June 15th total of 15,460,000 shares. Based on an average daily volume of 1,990,000 shares, the days-to-cover ratio is presently 7.1 days.July 16, 2024 | marketbeat.comCitius Pharmaceuticals Details Near-Term Milestones for Late-Stage CandidatesJuly 10, 2024 | prnewswire.comCitius Pharmaceuticals (NASDAQ:CTXR) Stock Price Up 13.7%Citius Pharmaceuticals (NASDAQ:CTXR) Shares Up 13.7%July 9, 2024 | marketbeat.comCitius Pharmaceuticals' (CTXR) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $4.00 price objective on shares of Citius Pharmaceuticals in a research note on Friday.May 31, 2024 | marketbeat.comCitius Pharmaceuticals (NASDAQ:CTXR) Trading Up 4.1%Citius Pharmaceuticals (NASDAQ:CTXR) Trading 4.1% HigherMay 31, 2024 | marketbeat.comCitius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock SolutionMay 29, 2024 | prnewswire.comCitius Pharma's 'Antibiotic Lock' Effective In Patients With Catheter-Associated Bloodstream InfectionsMay 21, 2024 | msn.comCitius gains as late-stage trial for Mino-Lok succeedsMay 21, 2024 | msn.comWhy Is Citius Pharmaceuticals (CTXR) Stock Up 11% Today?May 21, 2024 | investorplace.comCitius Pharma Announce Positive Topline Results For Pivotal Phase 3 Clinical Trial Of Mino-LokMay 21, 2024 | markets.businessinsider.comCitius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock SolutionMay 21, 2024 | prnewswire.comAnalysts Are Bullish on Top Healthcare Stocks: Autolus Therapeutics (AUTL), Citius Pharmaceuticals (CTXR)May 17, 2024 | markets.businessinsider.comCTXR Stock Earnings: Citius Pharma Meets EPS for Q2 2024May 14, 2024 | investorplace.com Get Citius Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CTXR and its competitors with MarketBeat's FREE daily newsletter. Email Address This Crypto Is Set to Explode in December (Ad)Discover our #1 crypto for the Trump Presidency Bull Run now! (Available for a Short Time) We highly recommend this hot altcoin before prices get too high Check it out by going here now CTXR Media Mentions By Week CTXR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CTXR News Sentiment▼0.430.78▲Average Medical News Sentiment CTXR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CTXR Articles This Week▼11▲CTXR Articles Average Week Get Citius Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CTXR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IMAB News Today ELYM News Today GBIO News Today HOWL News Today PYRGF News Today OVID News Today FBLG News Today AVTE News Today EPIX News Today PDSB News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CTXR) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
